Another article said: “The market for psychedelic drugs is projected to grow from just over $2 billion last year to about $6.9 billion by 2027, according to Data Bridge Market Research, which represents a blistering 16.3% compound annual growth rate over the forecast period.” The report authors note that psychedelic drugs are becoming increasingly accepted in the treatment of major depressive disorder, treatment-resistant depression, panic disorder, post-traumatic stress disorder, opiate addiction, eating disorders, and fibromyalgia, among other things.
The CFN article then focused on the investors, saying that: “The growing body of research supporting psychedelics and more widespread acceptance has led to an explosion of investment in the sector.
“The Magic Mushroom Company” BREAKING NEWS – MINERCO RETAINS LOBBYING FIRM TO SUPPORT EFFORTS TO DECRIMINALIZE PSILOCYBIN IN DETROIT AND SURROUNDING AREAS – Minerco, Inc.
Recreational and medical sales combined for $35 million in revenue in January 2020; by July 2020, the state was recording nearly $110 million in combined monthly sales.
“This is a pivotal time for our movement and for the psilocybin industry,” said Julius Jenge, Chief Executive Officer of Minerco, Inc.
Recent studies of the effects of psilocybin suggest it can be used to treat a wide range of ailments from insomnia to depression.
The study characterized the potential neuroreparative effect of psilocybin compared to being treated with a vehicle high dose psilocybin.
FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.
You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.